Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1

Interventions

pembrolizumab 14Gemcitabine 8Docetaxel 7Nivolumab 6durvalumab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5atezolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4sargramostim 3aldesleukin 3Specimen Handling 3Radiotherapy 3Paclitaxel 3Ipilimumab 3Fulvestrant 3Cisplatin 3Carboplatin 3venetoclax 2temsirolimus 2talazoparib 2spartalizumab 2olaparib 2liposomal doxorubicin 2fludarabine phosphate 2cabozantinib 2budigalimab 2avelumab 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Monatide (IMS 3015) × Breast × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡